One vital factor in prostate cancer (PCa) growth is androgen. Androgen effects are mediated through androgen-androgen receptor (A-AR) interaction that can then activate or repress its target genes. Based on this principle, androgen ablation therapy with various antiandrogens to treat PCa is still being used. However, many (if not all) PCa patients progress to an androgen-independent state leading to demise. Androgen is the only steroid hormone with two active forms (testosterone, T, vs. dihydrotestosterone, DHT) and all data thus far suggest only one AR gene exists. Further study of the mechanism of these two androgens will help determine how T or DHT can differentially regulate androgen target genes. This may allow us to develop a T- or DHT- specific antiandrogen that will help us to battle PCa with fewer side effects or prevent progression to an androgen-independent stage (because we only block one type of androgen without interfering with the action of the other type).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA055639-06A1
Application #
2697555
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Mohla, Suresh
Project Start
1992-02-01
Project End
2001-08-30
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Rochester
Department
Pathology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627